Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy.
David A. Reardon
Consultant or Advisory Role - Amgen; EMD Serono; Merck; Momenta Pharmaceuticals; Novartis; Roche/Genentech; Stemline Therapeutics
Honoraria - Merck; Roche/Genentech
Prafulla C. Gokhale
No relevant relationships to disclose
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U); Merck (U); Roche/Genentech (U)
Keith L. Ligon
No relevant relationships to disclose
Xiaoyun Liao
No relevant relationships to disclose
Scott J. Rodig
No relevant relationships to disclose
Jun Zhou
No relevant relationships to disclose
Lei Qin
No relevant relationships to disclose
Kristen Jones
No relevant relationships to disclose
Amy Sauer
No relevant relationships to disclose
Nancy E. Kohl
No relevant relationships to disclose
Glenn Dranoff
Consultant or Advisory Role - Novartis
Honoraria - Axon Advisors; Lilly; Merck; Roche/Genentech
Research Funding - Bristol-Myers Squibb (I); Novartis
Gordon James Freeman
Consultant or Advisory Role - Costim Pharmaceuticals (I); Costim Pharmaceuticals
Stock Ownership - Costim Pharmaceuticals